{"schema_version":"secwatch.filing_event.v1","accession":"0001439222-26-000071","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2026-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.294941+00:00","generated_at":"2026-05-15T01:41:54.330305+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Agios Q1 mitapivat revenue $20.7M; 242 AQVESME scrips; sCD sNDA plan in Q2","bullets":["Worldwide mitapivat net revenue $20.7M in Q1 2026, up from $8.7M in Q1 2025.","242 AQVESME prescriptions for thalassemia by U.S. REMS-certified physicians as of March 31, 2026.","Plans to submit mitapivat sNDA for sickle cell disease under accelerated approval pathway in Q2 2026.","Net loss $99.1M in Q1 2026 vs $89.3M in Q1 2025.","Cash and equivalents $1.0B as of March 31, 2026, down from $1.2B at Dec 31, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001439222-26-000071","json":"https://secwatch.observer/filing/0001439222-26-000071.json","markdown":"https://secwatch.observer/filing/0001439222-26-000071.md","text":"https://secwatch.observer/filing/0001439222-26-000071.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000071/0001439222-26-000071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000071/agio-20260429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T01:41:54.330305+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"34b058a6c5d7cef4186a4d98bdaf0205b83f0272","claim":"AGIOS PHARMACEUTICALS, INC. reported the quarter ended March 31, 2026 results: net income $99.1 million.","evidence_excerpt":"For the quarter ended March 31, 2026, net loss was $99.1 million, compared to net loss of $89.3 million for the quarter ended March 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000071/0001439222-26-000071-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Net income","value":"$99.1 million"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}